MedTrace Logo

Trajectories of FEV1 After Lung Transplantation

NCT05934617 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 2500

Last updated 2024-05-16

No results posted yet for this study

Summary

For individuals with ESLD, lung transplantation is the best, or only treatment option with increased pulmonary function and quality of life. The forced expiratory volume in one second (FEV1) is the standard to monitor the lung function after transplantation. The goal of this study is to identify and validate the FEV1 trajectories after lung transplantation, as well as their determinants and outcomes, using an international cohort of lung recipients.

Conditions

  • Lung Transplant Failure and Rejection
  • Chronic Lung Allograft Dysfunction

Sponsors & Collaborators

  • Paris Translational Research Center for Organ Transplantation

    lead OTHER

Principal Investigators

  • Antoine Roux, MD, PhD · Foch hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2021-01-01
Completion
2024-07-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05934617 on ClinicalTrials.gov